Looking for a District of Columbia Seroquel lawyer? Get in touch with one of our District of Columbia Seroquel lawyers now.
Home : Unsafe Drugs : Seroquel : News Articles
Seroquel - News Articles
-
March 5 (Bloomberg) -- AstraZeneca Plc officials opposed changing the wording of the antipsychotic drug Seroquel's ... -
Because weight gain is in fact a fairly common side effect of Seroquel, the PMCPA ruled that the company's ad was misleading and had breached ethical code requirements that marketing information should be “accurate and fair, and be capable of substantiation”, according to the Financial ... -
Following the lead of the US Food and Drug Administration in December, the committee recommended quetiapine fumarate (Seroquel) be approved for registration to treat general anxiety in adults in whom alternative therapies were not well tolerated or not effective.... ... -
Washington, DE: No fewer than 26000 lawsuits alleging problems with Seroquel and its potential for causing diabetes and other Seroquel side effects are ... -
Jul 4, 2008
Medical News Today (press release), UK -
AstraZeneca announced the online publication of long-term SEROQUEL® (quetiapine fumarate) clinical trial data in the Journal of Affective Disorders. Results show that SEROQUEL in combination with lithium or divalproex significantly increased the time to recurrence of any ... -
Jul 13, 2008
istockAnalyst.com, OR -
On July 1st, the US District Court for the District of New Jersey granted AstraZeneca's motion for summary judgment that its patent on quetiapine fumarate, ... -
Jul 24, 2008
Trading Markets (press release), CA -
LONDON, Jul 24, 2008 (Thomson Financial via COMTEX) -- AZN | Quote | Chart | News | PowerRating -- AstraZeneca Plc. revenues are expected to hold up, ... -
Jul 3, 2008
Therapeutics Daily (subscription) (press release), PA -
Spending on statins, drugs used to reduce artery-clotting cholesterol, jumped to almost $20 billion between 2000 and 2005, from $8 billion, according to a report from the federal Agency for Healthcare Research and Quality. """"`That amounts ... -
Jul 3, 2008
newratings.com, Germany -
LONDON, July 3 (newratings.com) - Analysts at Credit Suisse maintain their "neutral" rating on AstraZeneca Plc (AZN-GBX). The target price has been raised from 2230p to 2300p. In a research note published this morning, the analysts mention that the company has ... -
Jul 3, 2008
Trading Markets (press release), CA -
Jul 03, 2008 (Datamonitor via COMTEX) -- TEVA | Quote | Chart | News | PowerRating -- AstraZeneca has announced that the US District Court of New Jersey has granted the company's motion for summary judgment of no inequitable conduct. ...
-
Jul 3, 2008
Pharmaceutical Business Review -
By Staff Writer AstraZeneca had sued Teva Pharmaceutical Industries and Sandoz, alleging infringement of AstraZeneca's patent as a result of Teva's and ... -
Jul 3, 2008
MarketWatch -
By Val Brickates Kennedy, MarketWatch BOSTON (MarketWatch) -- The benchmark drug-stock indexes rose for a second day Thursday, boosted once again by strong buying of shares of European drug makers. ... -
Jul 3, 2008
Financial Times, UK -
By Andrew Jack Shares in AstraZeneca rose nearly 5 per cent yesterday after a US legal ruling pushed back the likely launch of a generic version of Seroquel , its blockbuster schizophrenia medicine, until 2011. The US District Court of New York granted the Anglo-Swedish pharmaceutical group's ... -
Jul 31, 2008
Pharma Times (subscription), UK -
AstraZeneca’s second quarter financials show healthy rises in sales and profits and the firm has raised its full-year earnings guidance, while hailing its performance in the emerging markets. Core operating profit increased 3% to $2.74 billion, while sales at constant exchange ... -
Jul 31, 2008
ShareCast, UK -
LONDON (SHARECAST) - AstraZeneca stormed higher Thursday as the drug major bumped up guidance for core annual earnings per share by 15 cents following better than expected second quarter numbers. Sales jumped 9% on a reported basis during the ... -
Jul 31, 2008
The News Journal, DE -
By ANDREW EDER • The News Journal • July 31, 2008 AstraZeneca PLC reported a 13 percent rise in net income for the second quarter, aided by growing sales for its key brands and a weak U.S. dollar. The London-based drug maker said today that net income ... -
Jul 31, 2008
Wall Street Journal -
By ELENA BERTON LONDON -- AstraZeneca PLC on Thursday reported a 13% rise in second-quarter net income, helped by strong sales of cholesterol drug Crestor and a weak U.S. dollar, as the company lifted its full-year outlook. The U.K.'s second-largest drug ... -
Jul 31, 2008
MarketWatch -
By Steve Goldstein, MarketWatch LONDON (MarketWatch) -- AstraZeneca on Thursday lifted its annual earnings view after reporting a 14% second-quarter profit rise, as the company said it benefited from a weak dollar and cost cutting. ... -
Jul 31, 2008
Forbes, NY -
LONDON (Thomson Financial) - AstraZeneca Plc. said it remains on track to achieve increased financial targets for the year after it beat estimates with a brisk rise in second-quarter sales and pretax profits and said it continues to strengthen its pipeline. ... -
Friday, August 01, 2008
About.com - Drugs, NY -
Risperdal (risperidone), and Seroquel(quetiapine), have added warnings to their prescription labels indicating an increased risk of type 2 diabetes. ...
Looking for a District of Columbia Seroquel lawyer? Get in touch with one of our District of Columbia Seroquel lawyers now.
Pages: 1 2 3 4 5 6 ... Next
